Suppr超能文献

慢性肾脏病3至5期强化与非强化降压治疗与死亡风险的关联:一项系统评价和荟萃分析

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

作者信息

Malhotra Rakesh, Nguyen Hoang Anh, Benavente Oscar, Mete Mihriye, Howard Barbara V, Mant Jonathan, Odden Michelle C, Peralta Carmen A, Cheung Alfred K, Nadkarni Girish N, Coleman Ruth L, Holman Rury R, Zanchetti Alberto, Peters Ruth, Beckett Nigel, Staessen Jan A, Ix Joachim H

机构信息

Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, La Jolla.

Imperial Valley Family Care Medical Group, El Centro, California.

出版信息

JAMA Intern Med. 2017 Oct 1;177(10):1498-1505. doi: 10.1001/jamainternmed.2017.4377.

Abstract

IMPORTANCE

Trials in patients with hypertension have demonstrated that intensive blood pressure (BP) lowering reduces the risk of cardiovascular disease and all-cause mortality but may increase the risk of chronic kidney disease (CKD) incidence and progression. Whether intensive BP lowering is associated with a mortality benefit in patients with prevalent CKD remains unknown.

OBJECTIVES

To conduct a systematic review and meta-analysis of randomized clinical trials (RCTs) to investigate if more intensive compared with less intensive BP control is associated with reduced mortality risk in persons with CKD stages 3 to 5.

DATA SOURCES

Ovid MEDLINE, Cochrane Library, EMBASE, PubMed, Science Citation Index, Google Scholar, and clinicaltrials.gov electronic databases.

STUDY SELECTION

All RCTs were included that compared 2 defined BP targets (either active BP treatment vs placebo or no treatment, or intensive vs less intensive BP control) and enrolled adults (≥18 years) with CKD stages 3 to 5 (estimated glomerular filtration rate <60 mL/min/1.73 m2) exclusively or that included a CKD subgroup between January 1, 1950, and June 1, 2016.

DATA EXTRACTION AND SYNTHESIS

Two of us independently evaluated study quality and extracted characteristics and mortality events among persons with CKD within the intervention phase for each trial. When outcomes within the CKD group had not previously been published, trial investigators were contacted to request data within the CKD subset of their original trials.

MAIN OUTCOME AND MEASURE

All-cause mortality during the active treatment phase of each trial.

RESULTS

This study identified 30 RCTs that potentially met the inclusion criteria. The CKD subset mortality data were extracted in 18 trials, among which there were 1293 deaths in 15 924 participants with CKD. The mean (SD) baseline systolic BP (SBP) was 148 (16) mm Hg in both the more intensive and less intensive arms. The mean SBP dropped by 16 mm Hg to 132 mm Hg in the more intensive arm and by 8 mm Hg to 140 mm Hg in the less intensive arm. More intensive vs less intensive BP control resulted in 14.0% lower risk of all-cause mortality (odds ratio, 0.86; 95% CI, 0.76-0.97; P = .01), a finding that was without significant heterogeneity and appeared consistent across multiple subgroups.

CONCLUSIONS AND RELEVANCE

Randomization to more intensive BP control is associated with lower mortality risk among trial participants with hypertension and CKD. Further studies are required to define absolute BP targets for maximal benefit and minimal harm.

摘要

重要性

高血压患者试验表明,强化降压可降低心血管疾病风险和全因死亡率,但可能增加慢性肾脏病(CKD)发病及进展风险。强化降压是否与已患CKD患者的死亡率获益相关尚不清楚。

目的

对随机临床试验(RCT)进行系统评价和荟萃分析,以研究与较低强度血压控制相比,强化血压控制是否与3至5期CKD患者的死亡风险降低相关。

数据来源

Ovid MEDLINE、Cochrane图书馆、EMBASE、PubMed、科学引文索引、谷歌学术和clinicaltrials.gov电子数据库。

研究选择

纳入所有比较两个明确血压目标(活性血压治疗与安慰剂或不治疗,或强化与较低强度血压控制)的RCT,且仅纳入3至5期CKD(估计肾小球滤过率<60 mL/min/1.73 m²)的成年人(≥18岁),或纳入1950年1月1日至2016年6月1日期间包含CKD亚组的试验。

数据提取与合成

我们两人独立评估研究质量,并提取每个试验干预阶段CKD患者的特征和死亡事件。当CKD组的结果此前未发表时,联系试验研究者索取其原始试验CKD亚组的数据。

主要结局与指标

每个试验活性治疗阶段的全因死亡率。

结果

本研究确定了30项可能符合纳入标准的RCT。18项试验提取了CKD亚组的死亡率数据,其中15924例CKD参与者中有1293例死亡。强化组和较低强度组的平均(标准差)基线收缩压(SBP)均为148(16)mmHg。强化组SBP平均下降16 mmHg至132 mmHg,较低强度组下降8 mmHg至140 mmHg。与较低强度血压控制相比,强化血压控制使全因死亡风险降低14.0%(比值比,0.86;95%CI,0.76 - 0.97;P = 0.01),这一结果无显著异质性,且在多个亚组中似乎一致。

结论与意义

随机分配至强化血压控制与高血压合并CKD试验参与者的较低死亡风险相关。需要进一步研究来确定最大获益和最小伤害的绝对血压目标。

相似文献

2
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.肾素抑制剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD007066. doi: 10.1002/14651858.CD007066.pub3.
6
Dietary interventions for adults with chronic kidney disease.针对成年慢性肾病患者的饮食干预措施。
Cochrane Database Syst Rev. 2017 Apr 23;4(4):CD011998. doi: 10.1002/14651858.CD011998.pub2.
10
Antiplatelet agents and anticoagulants for hypertension.抗血小板药物和抗凝剂治疗高血压。
Cochrane Database Syst Rev. 2022 Jul 28;7:CD003186. doi: 10.1002/14651858.CD003186.pub4.

引用本文的文献

7
Impact of intensive blood pressure control on kidney outcomes.强化血压控制对肾脏结局的影响。
Curr Opin Nephrol Hypertens. 2025 May 1;34(3):224-231. doi: 10.1097/MNH.0000000000001070. Epub 2025 Mar 7.

本文引用的文献

2
Trends in Prevalence of Chronic Kidney Disease in the United States.美国慢性肾脏病患病率的趋势
Ann Intern Med. 2016 Oct 4;165(7):473-481. doi: 10.7326/M16-0273. Epub 2016 Aug 2.
7
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
8
Meta-analysis in clinical trials revisited.再谈临床试验中的荟萃分析。
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45. doi: 10.1016/j.cct.2015.09.002. Epub 2015 Sep 4.
9
Blood pressure targets in CKD.慢性肾脏病的血压目标
Adv Chronic Kidney Dis. 2015 Mar;22(2):96-101. doi: 10.1053/j.ackd.2014.08.001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验